Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
Open Orphan (LSE:ORPH) is a popular healthcare stock: not a biotech but a pharmaceutical services business. That means it doesn’t engage in the risky and costly R&D of drug development. Instead it provides all the background data management and clinical trial services for vaccine and antiviral giants worldwide. Its clients include the likes of Pfizer and Johnson & Johnson.
It is most famous for helping to run the world’s first Covid-19 human challenge trials, winning a £46m UK government contract in October 2020. It also plans to spin off at least four major assets into separate companies. These include selling its novel disease data platform Disease in Motion to wearables giants like Google and Fitbit. Because I already own ORPH, I’ll get shares in each of these new companies in my Stocks and Shares ISA when that happens.
Because it is listed on AIM, it’s a relatively riskier buy than a company on the FTSE 250 or FTSE 100. Companies on this market have less stringent financial reporting requirements than on the higher tier.
Executive Chair Cathal Friel recently put a $1bn (£720m) valuation target on Open Orphan. That would give the business a share price of around £1.10, 266% higher than today’s 30p price
I agree with this. They see value but need to go under radar (3%) because of Woodford scandal. Makes sense.
Open Orphan on at about 18:30
https://event.webinarjam.com/register/945/5vv20b3vp
Presentation just around the corner
https://twitter.com/chasrutledge/status/1368844549049696257?s=20
I am not touching my orph shares.
I picked up some mogp shares before Raglan capital tr1 as i just wanted a punt at a fresh spac. I had no idea Cathal was getting in also. Weird!
And a waste of time in my opinion. Reddit is not a friendly place. I only put up 1 or 2 posts and got a response back which was not nice. Telling me I had a rubbish name and my bots (whatever they are) are obvious. I have deleted the app and would not recommend it. I do not think we want inverters from there .
Here you go. This was 4 months ago. We can add posts to it and start on Reddit.
https://www.reddit.com/r/IRISHTIMESauto/comments/jekap5/business_open_orphan_subsidiary_hvivo_signs_deal/
Ajbell prez
https://youtu.be/MOtzXF9uowc
News coverage for china.
https://youtu.be/Bk7fSrl26_8
Whats this? something on twitter. Any ideas?
Good days work lads! #orpharmy
Orph is expanding and other assets will become their own companies that you will get shares in. Open Orphan is core business. Other assets include Prep, Imutex, DIM, Digital data base. you could receive shares or dividend in these. Please correct me if I am wrong. I do not have data at hand.
“I think if you focus on the share price you get distracted, our job is running the company, deliver the results, the share price will follow.”
With value building up fast, Friel is considering spinning some of the non-core pharma assets – inherited when Hvivo was bolted on – into a separate listing on the London Stock Exchange.
“That would be my fourth successful IPO, a record for any person in Ireland.”
Open Orphan’s time has come thanks in large part to the defining health emergency of our time, the kind of pandemic that has not been seen in a century and the first one of its scale to be confronted by modern health systems, in the rich world at least.
Staying put: Cathal Friel says as long as Open Orphan’s share price keeps doubling he won’t be cashing out. Photo: Jason Clarke
‘In came the pandemic and suddenly being the world leader for a vaccine got kind of interesting’
February 11, 2021 by Ellie Donelly
Financier Cathal Friel is a familiar figure in Irish business. Over the years he has worked in finance, oil and gas, technology and media, but it is in his current project, Open Orphan, where he appears to have caught lightning in a bottle.
Open Orphan was only set up in 2017 as a niche pharmaceutical services company.
Two years later, Friel engineered a reverse takeover of stock market Venn Life Sciences – struggling at the time but already established on the Irish stock exchange and able to tap fresh investment.
From a standing start four years ago, Open Orphan’s shares are now valued at around £200m (€228m).
A big reason for that is that the pandemic means the world of diseases and their treatments is now the most critically important business on earth.
“For the first time in my life the hand of God came, instead of another disaster and the company blowing up. In came the pandemic and suddenly by April [2020] being the world leader for a vaccine got kind of interesting and the rest is history,” Friel says in his light Donegal accent.
Open Orphan’s Hvivo subsidiary is a world leader in testing anti-viral treatments on humans. Its purpose-built quarantine unit in London’s Whitechapel has 24 ensuite bedrooms where test volunteers live around the clock.
Why would we sell when the greatest gold rush in infectious diseases is just starting?
“Last year, being the world leader in what was a tiny niche had become really sexy, our share price has gone up.”
Would Friel, a former director of Merrion Stockbrokers who has seen the tops of other markets before and is Open Orphan’s biggest shareholder, considering selling now?
“If you think about it, why would we sell when the greatest gold rush in infectious diseases is just starting? We’d have no interest in selling the company at this stage,” he says.
“Our share price keeps doubling every 12 months. Where would you put your money if you can double it every 12 months? I’d still be one of the biggest shareholders, my view would be okay, yes, the company could be sold but where could I put my money where I’d be guaranteed to double it every 12 months other than leave it in Open Orphan?
“Provided the share price keeps doubling we’ll stay put,” he says.
“At the moment we have every capability to become a billion-dollar company.”
The share price is not the focus however.
His philosophy to managing the company is simple: “do the business, deliver the results and the share price will look after itself.”
“I think if you focus on the share price you get distracted, our job is running the company, deliver the results, the share price will follow.”
With value building up fast, Friel is considering spinning some of the non-core pharma assets –
Cathals presentation
https://vimeo.com/509092685
WTF so its out! I know what i will be doing tonight. :-)
Not what you think... Just having a beer and watchin prz.
Look at that finish!!! 28.50 on google SWEET!
Well said Trader 3.